{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '10.', 'Drug Development and Drug Interactions: Table of Substrates, Inhibitors and', 'Inducers (FDA, 2016).', '11.', 'Common Terminology Criteria for Adverse Events, Version 4.0, DCTD, NCI,', 'NIH, DHHS. 28 May 2009 [cited 29 Sept 2016]. Available from:', 'ittps://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-', '14_QuickReference_5x7.pdf.', '12.', 'Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in', 'solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer.', '2009;45(2):228-47.', '13.', 'Aaronson N, Ahmedzai S, Bergman B, et al. The European Organization for', 'Research and Treatment of Cancer QLQC30: a quality-of-life instrument for use in', 'international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-76.', '14.', \"AbbVie Stemcentrx LLC. Investigator's Brochure for Rovalpituzumab Tesirine\", '(SC 16LD6.5) Edition 5.0. 13 September 2016.', '15.', 'Food and Drug Administration. Guidance for industry clinical trial endpoints for', 'the approval of cancer drugs and biologics. 2007.', '16.', 'AbbVie. Coding Guidelines for MedDRA Term Selection, AbbVie Global', 'Pharmaceutical Research and Development (GPRD), Global Pharmacovigilance', 'and Clinical Project Team. Current version on file at AbbVie.', '17.', 'International Conference on Harmonisation. Guidance for Industry, E6 Good', 'Clinical Practice: Consolidated Guidance. April 1996.', '18.', 'International Conference on Harmonisation. Guideline for Industry, Clinical safety', 'data management: definitions and standards for expedited reporting, E2A.', 'March 1995.', '19.', 'AbbVie. Rovalpituzumab Tesirine Dear Rova-T Investigator Letter. 05 December', '2018.', '116']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix A.', 'Responsibilities of the Clinical Investigator', 'Clinical research studies sponsored by AbbVie are subject to the Good Clinical Practices', '(GCP) and local regulations and guidelines governing the study at the site location. In', 'signing the Investigator Agreement in Section 14.0 of this protocol, the investigator is', 'agreeing to the following:', '1.', 'Conducting the study in accordance with the relevant, current protocol, making', 'changes in a protocol only after notifying AbbVie, except when necessary to', 'protect the safety, rights or welfare of subjects.', '2.', 'Personally conducting or supervising the described investigation(s).', '3.', 'Informing all subjects, or persons used as controls, that the drugs are being used for', 'investigational purposes and complying with the requirements relating to informed', 'consent and ethics committees (e.g., independent ethics committee [IEC] or', 'institutional review board [IRB]) review and approval of the protocol and', 'amendments.', '4.', 'Reporting adverse experiences that occur in the course of the investigation(s) to', 'AbbVie and the site director.', '5.', \"Reading the information in the Investigator's Brochure/safety material provided,\", 'including the instructions for use and the potential risks and side effects of the', 'investigational product(s).', '6.', 'Informing all associates, colleagues, and employees assisting in the conduct of the', 'study about their obligations in meeting the above commitments.', '7.', 'Maintaining adequate and accurate records of the conduct of the study, making', 'those records available for inspection by representatives of AbbVie and/or the', 'appropriate regulatory agency, and retaining all study-related documents until', 'notification from AbbVie.', '8.', 'Maintaining records demonstrating that an ethics committee reviewed and', 'approved the initial clinical investigation and all amendments.', '117']\n\n###\n\n", "completion": "END"}